Literature DB >> 33174444

Why new biology must be uncovered to advance therapeutic strategies for chronic obstructive pulmonary disease.

Jennifer M K Nguyen1,2, Douglas N Robinson1,2,3, Venkataramana K Sidhaye3.   

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by the destruction of alveolar tissue (in emphysema) and airway remodeling (leading to chronic bronchitis), which cause difficulties in breathing. It is a growing public health concern with few therapeutic options that can reverse disease progression or mortality. This is in part because current treatments mainly focus on ameliorating symptoms induced by inflammatory pathways as opposed to curing disease. Hence, emerging research focused on upstream pathways are likely to be beneficial in the development of efficient therapeutics to address the root causes of disease. Some of these pathways include mitochondrial function, cytoskeletal structure and maintenance, and airway hydration, which are all affected by toxins that contribute to COPD. Because of the complexity of COPD and unknown targets for disease onset, simpler model organisms have proved to be useful tools in identifying disease-relevant pathways and targets. This review summarizes COPD pathology, current treatments, and therapeutic discovery research, with a focus on the aforementioned pathways that can advance the therapeutic landscape of COPD.

Entities:  

Keywords:  airway and alveolar epithelium; cigarette smoke; cytoskeleton; mitochondria; model organisms

Mesh:

Year:  2020        PMID: 33174444      PMCID: PMC7847061          DOI: 10.1152/ajplung.00367.2020

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  65 in total

Review 1.  Mitochondria: at the crossroads of regulating lung epithelial cell function in chronic obstructive pulmonary disease.

Authors:  Mahyar Aghapour; Alexander H V Remels; Simon D Pouwels; Dunja Bruder; Pieter S Hiemstra; Suzanne M Cloonan; Irene H Heijink
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-11-06       Impact factor: 5.464

2.  Functional Effects of Cigarette Smoke-Induced Changes in Airway Smooth Muscle Mitochondrial Morphology.

Authors:  Bharathi Aravamudan; Michael Thompson; Gary C Sieck; Robert Vassallo; Christina M Pabelick; Y S Prakash
Journal:  J Cell Physiol       Date:  2016-09-21       Impact factor: 6.384

Review 3.  Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.

Authors:  Lazaros I Sakkas; Athanasios Mavropoulos; Dimitrios P Bogdanos
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

4.  The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.

Authors:  Simon Lea; Alexandra Metryka; Jian Li; Andrew Higham; Charles Bridgewood; Gino Villetti; Maurizio Civelli; Fabrizio Facchinetti; Dave Singh
Journal:  Cytokine       Date:  2019-07-15       Impact factor: 3.861

5.  Role of IL-17A in murine models of COPD airway disease.

Authors:  Haruhiko Yanagisawa; Mitsuo Hashimoto; Shunsuke Minagawa; Naoki Takasaka; Royce Ma; Catherine Moermans; Saburo Ito; Jun Araya; Alison Budelsky; Amanda Goodsell; Jody L Baron; Stephen L Nishimura
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-12-02       Impact factor: 5.464

Review 6.  Experimental animal models for COPD: a methodological review.

Authors:  Vahideh Ghorani; Mohammad Hossein Boskabady; Mohammad Reza Khazdair; Majid Kianmeher
Journal:  Tob Induc Dis       Date:  2017-05-02       Impact factor: 2.600

7.  Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.

Authors:  Asger Reinstrup Bihlet; Morten Asser Karsdal; Jannie Marie Bülow Sand; Diana Julie Leeming; Mustimbo Roberts; Wendy White; Russell Bowler
Journal:  Respir Res       Date:  2017-01-19

8.  Myh10 deficiency leads to defective extracellular matrix remodeling and pulmonary disease.

Authors:  Hyun-Taek Kim; Wenguang Yin; Young-June Jin; Paolo Panza; Felix Gunawan; Beate Grohmann; Carmen Buettner; Anna M Sokol; Jens Preussner; Stefan Guenther; Sawa Kostin; Clemens Ruppert; Aditya M Bhagwat; Xuefei Ma; Johannes Graumann; Mario Looso; Andreas Guenther; Robert S Adelstein; Stefan Offermanns; Didier Y R Stainier
Journal:  Nat Commun       Date:  2018-11-02       Impact factor: 14.919

9.  The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.

Authors:  Dave Singh; Katharine Abbott-Banner; Thomas Bengtsson; Kenneth Newman
Journal:  Eur Respir J       Date:  2018-11-01       Impact factor: 16.671

10.  Mitochondrial dysfunction in human primary alveolar type II cells in emphysema.

Authors:  Beata Kosmider; Chih-Ru Lin; Loukmane Karim; Dhanendra Tomar; Liudmila Vlasenko; Nathaniel Marchetti; Sudhir Bolla; Muniswamy Madesh; Gerard J Criner; Karim Bahmed
Journal:  EBioMedicine       Date:  2019-08-02       Impact factor: 8.143

View more
  3 in total

1.  Human lung cDC1 drive increased perforin-mediated NK cytotoxicity in chronic obstructive pulmonary disease.

Authors:  Alexander M Pallazola; Jessica X Rao; Dawit T Mengistu; Maria S Morcos; Mariam S Toma; Valerie R Stolberg; Alexandra Tretyakova; Lisa McCloskey; Jeffrey L Curtis; Christine M Freeman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-27       Impact factor: 6.011

2.  The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review.

Authors:  Zhiping Xu; Lingxia Zhu; Jingye Zhan; Lijun Liu
Journal:  Eur J Med Res       Date:  2021-10-14       Impact factor: 2.175

3.  Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis.

Authors:  Mingming Deng; Yan Yin; Qin Zhang; Xiaoming Zhou; Gang Hou
Journal:  Front Immunol       Date:  2021-05-21       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.